
Peter Lio
Articles
-
3 weeks ago |
dermatologytimes.com | Renata Block |Peter Lio |Kaitlyn Bader
In the first episode of the new Derm Dispatch series, host Renata Block, MMS, PA-C, a board-certified physician assistant in Chicago, Illinois, and a Dermatology Times Editorial Advisory Board member, and guest Peter Lio, MD, a board-certified dermatologist and clinical assistant professor of dermatology and pediatrics at the Northwestern Feinberg School of Medicine in Chicago, Illinois, discuss integrative approaches to managing eczema, including the use of holistic treatments, and how to...
-
1 month ago |
healio.com | Gabrielle Capaldo |Kristen Dowd |Peter Lio
Key takeaways: Clinicians should discuss the role of diet with patients looking for nutritional solutions for atopic dermatitis. While certain diets can be harmful, evidence suggests anti-inflammatory diets are beneficial. ORLANDO — Nutrition plays a role in the management of atopic dermatitis, according to research presented at the American Academy of Dermatology Annual Meeting.
-
1 month ago |
dermatologytimes.com | Emma Andrus |Peter Lio
Peter Lio, MD, a clinical assistant professor of dermatology and pediatrics at Northwestern University, recently presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.
-
1 month ago |
patientcareonline.com | Peter Lio |Grace Halsey
Peter A Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, made this promise during an interview with Patient Care leading up to the 2025 American Academy of Dermatology meeting being held March 7-11, in Orlando, FL. His topic was diet and eczema and more specifically how infrequently a skin reaction that brings a child or adult into the clinic is the result of ingesting a food.
-
1 month ago |
healio.com | Gabrielle Capaldo |Kristen Dowd |Peter Lio
Key takeaways: If approved, this topical will offer a nonsteroidal option for caregivers and their children with atopic dermatitis. The FDA has set a target action date of Oct. 13. Editor’s note: This is a developing news story. Please check back soon for updates. The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years, according to a press release from the manufacturer.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →